Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II high-dose chemotherapy and autologous stem cell transplantation for aggressive T-cell lymphoma
2005-003906-27Phase 2Completed
- Sponsor
- University College London
- Start
- Nov 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, doxorubicin, vincristine, prednisolone, epirubicin and 7 more in aggressive T-cell lymphoma (PTCL), peripheral T-cell lymphoma (PTCL), enteropathy-associated T-cell lymphoma (EATL) and 3 more, sponsored by University College London. Primary endpoint: Survival at one year. Started Nov 2005; status: completed.
02
Drugs
cyclophosphamidedoxorubicinvincristineprednisoloneepirubicin
03
Conditions
aggressive T-cell lymphoma (PTCL)peripheral T-cell lymphoma (PTCL)enteropathy-associated T-cell lymphoma (EATL)hepatosplenic T-cell lymphoma (HSTCL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2005-003906-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003906-27.